avaloinvestordeckseptemb。Katsuaki Maehara: Therapeutic development of 4th generation。First-in-Human Evaluation of 18F-PF-06445974, a PET。Next-generation EGFR tyrosine kinase inhibitors to overcome。「NEWエッセンシャル法医学」高取健彦 / 長尾正崇定価: ¥ 8800#高取健彦 #長尾正崇 #本 #自然/医療・薬学・健康